An Eli Lilly & Co. Zepbound injection pen organized within the Brooklyn borough of New York, US, on Thursday, March 28, 2024.
Shelby Knowles | Bloomberg | Getty Photographs
CVS Well being on Thursday mentioned it should restore protection of Eli Lilly‘s blockbuster weight reduction injection Zepbound and begin masking its new weight problems tablet on its commonplace drug plans – a win for the drugmaker and sure sufferers who will have the ability to entry extra remedy choices.
CVS will add Zepbound protection on Oct. 1, and begin masking Lilly’s newly authorized Foundayo tablet on June 1. The transfer will increase Lilly’s efforts to take care of its dominance over Novo Nordisk within the blockbuster weight reduction market, because it places the 2 firms on equal footing on main drug plans.
It comes a yr after CVS struck a deal with Novo Nordisk to make its drug Wegovy the popular weight problems remedy on its commonplace plans, whereas dropping protection of Zepbound. That meant sufferers on these plans would have needed to pay extra out of pocket or undergo further hurdles to get Lilly’s drug.
However GLP-1 medicines from each Lilly and Novo will quickly be co-preferred choices on CVS Caremark’s commonplace business formulary template – an inventory of coated medication that insurers and employers can select to undertake – which represents 25 million to 30 million People. Caremark is likely one of the nation’s largest pharmacy profit managers.
Plan sponsors that undertake Caremark’s commonplace formulary can nonetheless choose out of masking GLP-1s for weight reduction, so protection of Lilly’s and Novo’s remedies is not assured for all sufferers.
Nonetheless, CVS expects the transfer to drive 10% to fifteen% further financial savings throughout the burden administration class.
CVS on Thursday touted final yr’s settlement with Novo Nordisk as the primary transfer by a serious pharmacy profit supervisor to spur competitors within the GLP-1 market and “bend the price curve.” CVS mentioned each Lilly and Novo responded by partnering with the healthcare big to make GLP-1s for weight reduction extra inexpensive, pointing to “profitable continued pricing negotiations” with each drugmakers.
“With this expanded protection, tens of millions of People may have entry to Zepbound and Foundayo, giving sufferers and their medical doctors an actual alternative in how weight problems is handled,” Lilly mentioned in an announcement. “We’ll maintain working to make that true for everybody.”
Lilly added that its tablet might be coated by all three of the nation’s largest pharmacy profit managers, together with Caremark.
In an announcement, Novo mentioned it’s “happy” that the Wegovy injection and newly launched tablet with the identical identify will retain their most well-liked standing on CVS’ formularies. CVS Caremark sufferers can stay on these medication “with out interruption,” Novo added.
As a PBM, Caremark is employed by employers, authorities entities, unions and different well being plans to barter the price of medicines included on formularies chosen by plan sponsors.
“We’re creating entry and choices that may not have existed with out our management available in the market,” mentioned Ed DeVaney, CVS Caremark president, in a launch. “We acted boldly via lively engagement and negotiation with our drug producer companions to sort out affordability and entry for our clients and their members.”
CVS mentioned Caremark will guarantee a “clean transition” to coated therapies for patrons, consultants, suppliers and members.